← Leaderboards
Brian S Murphy
Eiger Group International, Inc.
$3,000,000
Attributed
$3,000,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2011–13$1M$750K$500K$250K$0
'11
'12
'13
Funding mix
By agency
NIH$3,000,000 · 1
By mechanism
R42$3,000,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Eiger Group International, Inc.
Same institution · by research overlap
- Coleman Gross$267,105
Others in their field
Top investigators on “Anti-Hepatitis C”
- Hanno Steen · Boston Children'S Hospital$8,166,924
- Jeffrey S Glenn · Stanford University$7,110,526
- Michael J Gale · University Of Texas Sw Med Ctr/Dallas$6,873,614
- Kimberly Page · University Of California San Francisco$6,568,803
- Charles M. Rice · Rockefeller University$6,433,318
- Brian H. Johnston · Somagenics, Inc.$5,394,061
Research focus
Anti-Hepatitis CAntihistaminesAntiviral AgentsBackBinding (Molecular Function)Canis FamiliarisClinicCohortCommercial ApplicationCommercializationData SetDoseDrug InteractionsDrug UsageExanthemaFoundationsFundingFutureGenerationsGenomeGenotypeHepatitis CHepatitis C VirusAnemia
Grant awards (3)
Advancing clemizole for hepatitis C: towards a pre-IND package--Phase II$1,000,000
R42 · FY2013 · AI · contact PI
Advancing clemizole for hepatitis C: towards a pre-IND package--Phase II$1,000,000
R42 · FY2012 · AI · contact PI
Advancing clemizole for hepatitis C: towards a pre-IND package--Phase II$1,000,000
R42 · FY2011 · AI · contact PI